TICKERNERD
Menu
LLYLLYHealthcare · Drug Manufacturers - General

LLY Stock Forecast: Eli Lilly & Co. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1,255
+0.83% on the day

The 29 Wall Street analysts covering Eli Lilly & Co. hold a median 12-month price target of $1,372 — +9.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.1T
Ticker Nerd rank
91 / 100
Median analyst target
$1,372
Analysts covering
29
Total return, dividends reinvested
1W
+6.3%
1M
+6.9%
YTD
+17.3%
1Y
+77.9%
From 52W high
−2.0%
From 52W low
+81.6%
$691
$1,280
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LLY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Eli Lilly & Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
91 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
99
Volatility
98
Value
97
Revisions
92
Growth
88
Momentum
83
Issuance
40
Accruals
21
Size
0

Quality (99): The business earns solid, repeatable profits on what it owns.

Accruals (21): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (0): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LLY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LLY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$600$800$1,000$1,200$1,400$1,600Oct 25Jan 26Apr 26Jul 26LLYHigh $1,600Median $1,372Low $850

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says29 analysts
23 Buy4 Hold2 Sell
Low $850Median $1,372High $1,600

The green dot is the last close — the median target sits +9.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 11 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
7 Aug 2026Truist SecuritiesMaintainsBuy$1,370 → $1,376
6 Aug 2026Cantor FitzgeraldMaintainsOverweight$1,350 → $1,410
6 Aug 2026Wells FargoMaintainsOverweight$1,280 → $1,330
15 July 2026CitigroupMaintainsBuy$1,500 → $1,600
15 July 2026CitigroupMaintainsBuy—
14 July 2026BernsteinMaintainsOutperform$1,300 → $1,385
14 July 2026BernsteinMaintainsOutperform—
13 July 2026GuggenheimMaintainsBuy—
13 July 2026GuggenheimMaintainsBuy$1,235 → $1,273
13 July 2026UBSMaintainsBuy—
13 July 2026UBSMaintainsBuy$1,250 → $1,425
10 July 2026B of A SecuritiesMaintainsBuy$1,251 → $1,334
10 July 2026B of A SecuritiesMaintainsBuy—
8 July 2026Morgan StanleyMaintainsOverweight—
8 July 2026Morgan StanleyMaintainsOverweight$1,344 → $1,347
8 July 2026RBC CapitalMaintainsOutperform$1,250 → $1,500
8 July 2026RBC CapitalMaintainsOutperform—
8 July 2026Truist SecuritiesMaintainsBuy$1,281 → $1,370
8 July 2026Truist SecuritiesMaintainsBuy—
7 July 2026JP MorganMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LLY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

LLY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.5%
Analysts raising
6
Analysts cutting
13
Fundamentals

Eli Lilly & Co. (LLY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
42.2×

Cheaper than 18% of US stocks

Price / sales
14.0×

Cheaper than 12% of US stocks

Price / book
33.0×

Cheaper than 3% of US stocks

EV / EBITDA
27.9×

Cheaper than 10% of US stocks

Growth & margins
Revenue growth (YoY)
47.7%

Higher than 86% of US stocks

Earnings growth (YoY)
25.3%

Higher than 63% of US stocks

Gross margin
85.8%

Higher than 94% of US stocks

Operating margin
54.2%

Higher than 97% of US stocks

Net margin
33.5%

Higher than 92% of US stocks

Returns & dividend
Return on equity
102.3%

Higher than 96% of US stocks

Return on assets
20.4%

Higher than 99% of US stocks

Dividend yield
0.6%

Higher than 11% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LLY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
LLYEli Lilly & Co.$1.1T
91
JNJJohnson & Johnson$650.8B
92
ABBVAbbVie, Inc.$468.1B
96
MRKMerck & Co., Inc.$378.6B
83
AMGNAmgen, Inc.$236.8B
92
GILDGilead Sciences, Inc.$181.4B
92
PFEPfizer Inc.$159.6B
79

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Eli Lilly & Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LLY news & analysis

3 Growth Stocks That Could Skyrocket in the Second Half of 2026

The Motley Fool · 24 Aug 2026neutral

The article highlights growth stocks that could perform strongly in the second half of 2026, citing Arista Networks' data center networking demand and margins and Micron's AI memory cycle revenue growth. Eli Lilly is not mentioned in the excerpt.

Why it matters — A Lilly watcher could note that this piece focuses on other sectors (networking and memory) and offers no direct insight or commentary on Eli Lilly's outlook.

Eli Lilly launches oral weight-loss pill Foundayo in UK

Reuters · 23 Aug 2026positive

Eli Lilly announced the launch of its oral pill Foundayo in the UK for weight management and type 2 diabetes. The UK becomes the first country in Europe where the treatment is available.

Why it matters — This marks the first European market entry for one of Lilly's oral weight-management and diabetes treatments, expanding the company's commercial footprint.

Prediction: Eli Lilly Could Be One of the Biggest Winners of the Next Decade. Here's Why.

24/7 Wall Street · 23 Aug 2026positive

Eli Lilly reported one of the most impressive quarters in Big Pharma history, according to 24/7 Wall Street. The article highlights the company's strong recent performance and positions it as a potential major winner over the next decade.

Why it matters — LLY watchers would note the company's standout quarterly results as a signal of its strong momentum and long-term growth prospects.

Billionaire Ken Griffin Just Loaded Up on Eli Lilly Stock. Should You?

The Motley Fool · 23 Aug 2026positive

Billionaire Ken Griffin's Citadel hedge fund nearly quadrupled its stake in Eli Lilly during the second quarter. The move comes as Lilly's diabetes and obesity drugs continue to show strong momentum.

Why it matters — A prominent institutional investor significantly increasing its position signals notable interest in Lilly's ongoing success with its diabetes and obesity drug portfolio.

Eli Lilly: Shaking Off Competition From The Dethroned Novo Nordisk

Seeking Alpha · 22 Aug 2026positive

The article reports Eli Lilly has strengthened its dominance in the global obesity drug market, outpacing Novo Nordisk despite intensifying competition and pricing pressures. LLY's US market share has plateaued at 60–61%, while rising total prescriptions and global expansion continue to support growth prospects, with valuation compressing to just over 30x forward earnings.

Why it matters — For LLY watchers, this highlights the company's competitive position and ongoing growth momentum in the obesity drug market amid valuation compression and competitive pricing pressures.

FAQ

Frequently asked questions about LLY stock

What is the LLY stock price forecast for 2026-2027?

The 29 Wall Street analysts covering Eli Lilly & Co. have a median 12-month price target of $1,372, with estimates ranging from $850 to $1,600. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LLY stock a buy right now?

Of the 29 analysts covering Eli Lilly & Co., 23 rate it a Buy, 4 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Eli Lilly & Co. 91 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LLY?

As at 22 Aug 2026, Eli Lilly & Co. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).

Will LLY stock go up?

No one can know that. What the data says: the median 12-month target from 29 analysts implies +9.3% from the last close, and Ticker Nerd's factor model ranks Eli Lilly & Co. 91 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LLY stock forecast for 2030?

No analyst covering Eli Lilly & Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LLY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $850 to $1,600 over the next 12 months.

How has LLY stock performed over the past year?

Eli Lilly & Co. returned +77.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Eli Lilly & Co. do?

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures, and markets medicines for human health. The company focuses on major therapeutic areas including cardiometabolic health, oncology, immunology, neuroscience, and rare diseases, with a portfolio that spans treatments for diabetes, obesity, cancer, autoimmune conditions, and neurological disorders.

What is the latest news on LLY?

The most recent item we track (The Motley Fool, 24 Aug 2026): "3 Growth Stocks That Could Skyrocket in the Second Half of 2026". The article highlights growth stocks that could perform strongly in the second half of 2026, citing Arista Networks' data center networking demand and margins and Micron's AI memory cycle revenue growth. Eli Lilly is not mentioned in the excerpt.

Company

About Eli Lilly & Co.

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures, and markets medicines for human health. The company focuses on major therapeutic areas including cardiometabolic health, oncology, immunology, neuroscience, and rare diseases, with a portfolio that spans treatments for diabetes, obesity, cancer, autoimmune conditions, and neurological disorders. Eli Lilly and Company also operates in animal health-related products in some markets, supporting a broader healthcare presence. Its business is centered on prescription medicines and biologic therapies, combining research, clinical development, and large-scale manufacturing to serve patients, healthcare providers, and health systems worldwide. Headquartered in Indianapolis, Indiana, Eli Lilly and Company is widely recognized for its role in advancing innovative treatments and maintaining a strong position in the global pharmaceutical market.

CEO Mr. David A. Ricks · 50,000 employees · United States · https://www.lilly.com